The file of the "Raw-data" is the raw data set.

BackgroundThe purpose of this study was to evaluate the relationship between hyperuricemia and the risks of all-cause mortality and cardiovascular disease (CVD) mortality in patients with osteoarthritis (OA).MethodsA retrospective cohort study was performed on 3,971 patients using data from the National Health and Nutrition Examination Survey database between 1999 and 2018. OA was diagnosed through specific questions and responses. The weighted COX regression models were used to explore the factors associated with all-cause mortality/CVD mortality in OA patients. Subgroup analyses were conducted based on age, gender, hypertension, dyslipidemia, CVD, and chronic kidney disease (CKD). Hazard ratio (HR) and 95% confidence interval (95% CI) were measured as the evaluation indexes.ResultsDuring the duration of follow-up time (116.38 ± 2.19 months), 33.69% (1,338 patients) experienced all-cause mortality, and 11.36% (451 patients) died from CVD. Hyperuricemia was associated with higher risks of all-cause mortality (HR: 1.22, 95% CI: 1.06–1.41, P = 0.008) and CVD mortality (HR: 1.32, 95% CI: 1.02–1.72, P = 0.036) in OA patients. Subgroup analyses showed that hyperuricemia was related to the risk of all-cause mortality in OA patients aged >65 years (HR: 1.17, 95% CI: 1.01–1.36, P = 0.042), in all male patients (HR: 1.41, 95% CI: 1.10–1.80, P = 0.006), those diagnosed with hypertension (HR: 1.17, 95% CI: 1.01–1.37, P = 0.049), dyslipidemia (HR: 1.18, 95% CI: 1.01–1.39, P = 0.041), CVD (HR: 1.30, 95% CI: 1.09–1.55, P = 0.004), and CKD (HR: 1.31, 95% CI: 1.01–1.70, P = 0.046). The association between hyperuricemia and a higher risk of CVD mortality was found in OA patients aged ≤ 65 years (HR: 1.90, 95% CI: 1.06–3.41, P = 0.032), who did not suffer from diabetes (HR: 1.36, 95% CI: 1.01–1.86, P = 0.048), who did not suffer from hypertension (HR: 2.56, 95% CI: 1.12–5.86, P = 0.026), and who did not suffer from dyslipidemia (HR: 2.39, 95% CI: 1.15–4.97, P = 0.020).ConclusionThese findings emphasize the importance of monitoring serum uric acid levels in OA patients for potentially reducing mortality associated with the disease.